Advances in the treatment of Parkinson's disease

[1]  D. Cardinali,et al.  Role of melatonin in neurodegenerative diseases , 2009, Neurotoxicity Research.

[2]  C. Chiueh,et al.  Neuroprotective strategies in parkinson’s disease: protection against progressive nigral damage induced by free radicals , 2009, Neurotoxicity Research.

[3]  R. Reiter,et al.  Melatonin and parkinson’s disease , 2005, Endocrine.

[4]  M. Youdim,et al.  Iron and α-synuclein in the substantia nigra of MPTP-treated mice , 2007, Journal of Molecular Neuroscience.

[5]  E. Melamed,et al.  Embryonic and adult stem cells as a source for cell therapy in Parkinson’s disease , 2007, Journal of Molecular Neuroscience.

[6]  R. Cools.  Dopaminergic modulation of cognitive function-implications for l-DOPA treatment in Parkinson's disease , 2006, Neuroscience & Biobehavioral Reviews.

[7]  W. Weiner.  Levodopa—toxic or neuroprotective? , 2006, Nature Clinical Practice Neurology.

[8]  W. Le,et al.  Neuroprotective Therapy in Parkinson Disease , 2006, American journal of therapeutics.

[9]  Hongjie Dai,et al.  Neural stimulation with a carbon nanotube microelectrode array. , 2006, Nano letters.

[10]  P. Brundin,et al.  Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. , 2006, International journal of pharmaceutics.

[11]  T. Aziz,et al.  Surgical insights into Parkinson's disease. , 2006, Journal of the Royal Society of Medicine.

[12]  P. Aebischer,et al.  Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease , 2006, Neurobiology of Disease.

[13]  Mark Stacy,et al.  Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease , 2006, Annals of neurology.

[14]  D. Nyholm.  Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease , 2006, Clinical pharmacokinetics.

[15]  T. Dawson,et al.  Role of nitric oxide in Parkinson's disease. , 2006, Pharmacology & therapeutics.

[16]  Tipu Z. Aziz,et al.  Towards a Demand Driven Deep-Brain Stimulator for the Treatment of Movement Disorders , 2005 .

[17]  Guo-qiang Lu,et al.  Involvement of proinflammatory factors, apoptosis, caspase-3 activation and Ca2+ disturbance in microglia activation-mediated dopaminergic cell degeneration , 2005, Mechanisms of Ageing and Development.

[18]  J. Brotchie,et al.  Advances in the delivery of treatments for Parkinson’s disease , 2005, Expert opinion on drug delivery.

[19]  Fabrizio Stocchi,et al.  Pathological gambling in Parkinson's disease , 2005, The Lancet Neurology.

[20]  J. McBride,et al.  Long-term NSAID use in primary care: changes over a decade and NICE risk factors for gastrointestinal adverse events. , 2005, Rheumatology.

[21]  Y. Geda,et al.  Pathological gambling caused by drugs used to treat Parkinson disease. , 2005, Archives of neurology.

[22]  Erwan Bezard,et al.  Protective effect of green tea polyphenols on the SH-SY5Y cells against 6-OHDA induced apoptosis through ROS-NO pathway. , 2005, Free radical biology & medicine.

[23]  J. Matsumoto,et al.  Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. , 2005, Parkinsonism & related disorders.

[24]  A. Björklund,et al.  Increased fiber outgrowth from xeno-transplanted human embryonic dopaminergic neurons with co-implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor , 2005, Brain Research Bulletin.

[25]  Tianhong Pan,et al.  Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. , 2005, Biochemical and biophysical research communications.

[26]  G. Bernardi,et al.  The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy? , 2005, Trends in pharmacological sciences.

[27]  S. Jana,et al.  Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson's disease. , 2005, Biochimica et biophysica acta.

[28]  Makoto Hashimoto,et al.  Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease , 2005, Neuron.

[29]  Ali Samii,et al.  Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis , 2005, The Lancet Neurology.

[30]  S. Przedborski.  Pathogenesis of nigral cell death in Parkinson's disease. , 2005, Parkinsonism & related disorders.

[31]  A. Schrag.  Entacapone in the treatment of Parkinson's disease , 2005, The Lancet Neurology.

[32]  Andreas Hald,et al.  Oxidative stress and inflammation in Parkinson's disease: is there a causal link? , 2005, Experimental Neurology.

[33]  Joseph Jankovic,et al.  Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations , 2005, Movement disorders : official journal of the Movement Disorder Society.

[34]  S. Mandel,et al.  Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives , 2005, Brain Research Reviews.

[35]  Rabi Simantov,et al.  Stem cells may reshape the prospect of Parkinson's disease therapy. , 2005, Brain research. Molecular brain research.

[36]  W Poewe,et al.  Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial , 2005, The Lancet.

[37]  M. Prato,et al.  Binding and condensation of plasmid DNA onto functionalized carbon nanotubes: toward the construction of nanotube-based gene delivery vectors. , 2005, Journal of the American Chemical Society.

[38]  H. Kaş,et al.  Carbidopa/levodopa-loaded biodegradable microspheres: in vivo evaluation on experimental Parkinsonism in rats. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[39]  M. Youdim,et al.  Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases , 2005, Mechanisms of Ageing and Development.

[40]  Keyi Yang,et al.  Gene Therapy for Parkinsons Disease: Progress and Challenges , 2005 .

[41]  G. Reynolds,et al.  Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain , 2005, Journal of Neural Transmission.

[42]  P. Carvey,et al.  Intra-parenchymal injection of tumor necrosis factor-α and interleukin 1-β produces dopamine neuron loss in the rat , 2005, Journal of Neural Transmission.

[43]  J. Brotchie,et al.  Levodopa-induced dyskinesia in Parkinson’s disease , 2005, Journal of neural transmission.

[44]  S. Dodig,et al.  The facts and controversies about selenium. , 2004, Acta pharmaceutica.

[45]  A. McLachlan,et al.  Declining melatonin levels and older people. How old is old? , 2004, Neuro endocrinology letters.

[46]  S. Dodig,et al.  The facts and controverses about selenium , 2004 .

[47]  M. Karásek.  Melatonin, human aging, and age-related diseases , 2004, Experimental Gerontology.

[48]  M. Emborg.  Evaluation of animal models of Parkinson's disease for neuroprotective strategies , 2004, Journal of Neuroscience Methods.

[49]  Y. Nakata,et al.  Involvement of alpha7- and alpha4beta2-type postsynaptic nicotinic acetylcholine receptors in nicotine-induced excitation of dopaminergic neurons in the substantia nigra: a patch clamp and single-cell PCR study using acutely dissociated nigral neurons. , 2004, Brain research. Molecular brain research.

[50]  Protective effect of liposome-mediated glial cell line-derived neurotrophic factor gene transfer in vivo on motoneurons following spinal cord injury in rats. , 2004, Chinese journal of traumatology = Zhonghua chuang shang za zhi.

[51]  M. Carafa,et al.  Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[52]  D. Nyholm,et al.  Levodopa Infusion Therapy in Parkinson Disease: State of the Art in 2004 , 2004, Clinical neuropharmacology.

[53]  M. Quik.  Smoking, nicotine and Parkinson's disease , 2004, Trends in Neurosciences.

[54]  H. Hefter,et al.  Is levodopa toxic? , 2004, Journal of Neurology.

[55]  M. Hallett,et al.  Levodopa in the treatment of Parkinson's disease: Current controversies , 2004, Movement disorders : official journal of the Movement Disorder Society.

[56]  M. Beal.  Mitochondrial Dysfunction and Oxidative Damage in Alzheimer's and Parkinson's Diseases and Coenzyme Q10 as a Potential Treatment , 2004, Journal of bioenergetics and biomembranes.

[57]  K. Bhojani,et al.  NSAIDs and kidney. , 2004, The Journal of the Association of Physicians of India.

[58]  T. Cooper,et al.  A Pulmonary Formulation of l-Dopa Enhances Its Effectiveness in a Rat Model of Parkinson's Disease , 2004, Journal of Pharmacology and Experimental Therapeutics.

[59]  P. Bauer,et al.  Overexpression of glial cell line-derived neurotrophic factor induces genes regulating migration and differentiation of neuronal progenitor cells. , 2004, Experimental cell research.

[60]  Robert Nitsch,et al.  Selenium and brain function: a poorly recognized liaison , 2004, Brain Research Reviews.

[61]  M. Vila,et al.  Genetic clues to the pathogenesis of Parkinson's disease , 2004, Nature Medicine.

[62]  M. Youdim,et al.  Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax , 2004, Neuropharmacology.

[63]  S. Chunmeng,et al.  Skin: a promising reservoir for adult stem cell populations. , 2004, Medical hypotheses.

[64]  D. Standaert,et al.  Rationale for and use of NMDA receptor antagonists in Parkinson's disease. , 2004, Pharmacology & therapeutics.

[65]  J. Joseph,et al.  α-Synuclein Up-regulation and Aggregation during MPP+-induced Apoptosis in Neuroblastoma Cells , 2004, Journal of Biological Chemistry.

[66]  R. Dewey,et al.  Management of motor complications in Parkinson’s disease , 2004, Neurology.

[67]  P. Newhouse,et al.  Effects of nicotinic stimulation on cognitive performance. , 2004, Current opinion in pharmacology.

[68]  A. Beuter,et al.  Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[69]  M. Youdim,et al.  Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline , 2004, Neuroscience Letters.

[70]  Y. Teo,et al.  Alpha-synuclein haplotypes implicated in risk of Parkinson’s disease , 2004, Neurology.

[71]  B. Szende,et al.  (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. , 2004, Neurotoxicology.

[72]  M. Yamada,et al.  Clinical pharmacology of MAO inhibitors: safety and future. , 2004, Neurotoxicology.

[73]  V. Mok,et al.  Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease , 2003, Journal of the Neurological Sciences.

[74]  M. Anagnostouli,et al.  Plasma levels of antioxidant vitamins C and E are decreased in vascular parkinsonism , 2003, Journal of the Neurological Sciences.

[75]  M. Emre,et al.  Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[76]  M. Bédard,et al.  Poor Tolerability of a Transdermal Nicotine Treatment in Parkinson's Disease , 2003, Clinical neuropharmacology.

[77]  A. Schapira.  Neuroprotection in PD—A role for dopamine agonists? , 2003, Neurology.

[78]  K. Blomgren,et al.  Both apoptosis and necrosis occur early after intracerebral grafting of ventral mesencephalic tissue : a role for protease activation , 2016 .

[79]  T. Shimazoe,et al.  In vivo delivery of glial cell-derived neurotrophic factor across the blood-brain barrier by gene transfer into brain capillary endothelial cells. , 2003, Human gene therapy.

[80]  M. Kaplitt,et al.  Future and current surgical therapies in Parkinson's disease , 2003, Current opinion in neurology.

[81]  M. Berry,et al.  Selenium and selenoproteins in the brain and brain diseases , 2003, Journal of neurochemistry.

[82]  M. Beal.  Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.

[83]  Gordon H Baltuch,et al.  Deep brain stimulation for movement disorders: morbidity and mortality in 109 patients. , 2003, Journal of neurosurgery.

[84]  K. Mohanakumar,et al.  Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats , 2003, Brain Research.

[85]  Muzamil Ahmad,et al.  Dose‐dependent protective effect of selenium in rat model of Parkinson's disease: neurobehavioral and neurochemical evidences , 2003, Journal of neurochemistry.

[86]  C. Olanow,et al.  Levodopa Is Toxic to Dopamine Neurons in an in Vitro but Not an in Vivo Model of Oxidative Stress , 2003, Journal of Pharmacology and Experimental Therapeutics.

[87]  J. Jankovic,et al.  Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD , 2003, Neurology.

[88]  A. Schapira,et al.  Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease , 2003, Annals of neurology.

[89]  A. Rao,et al.  Free radical toxicity and antioxidants in Parkinson's disease. , 2003, Neurology India.

[90]  C. Olanow,et al.  Surgical therapy for Parkinson's disease. , 2002, European journal of neurology.

[91]  A. Schapira.  Dopamine agonists and neuroprotection in Parkinson's disease. , 2002, European journal of neurology.

[92]  Xiongwei Zhu,et al.  Mitochondrial abnormalities and oxidative imbalance in neurodegenerative disease. , 2002, Science of aging knowledge environment : SAGE KE.

[93]  M. Quik,et al.  Nicotine and nicotinic receptors; relevance to Parkinson's disease. , 2002, Neurotoxicology.

[94]  Treatment of advanced stage patients with Parkinson's disease. , 2002, Parkinsonism & related disorders.

[95]  J. Andersen,et al.  Glutathione, iron and Parkinson's disease. , 2002, Biochemical pharmacology.

[96]  Zhe-yu Chen,et al.  Cationic liposome-mediated GDNF gene transfer after spinal cord injury. , 2002, Journal of neurotrauma.

[97]  E. Esposito,et al.  A review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes , 2002, Neurobiology of Aging.

[98]  Aviva Abosch,et al.  Long-term Hardware-related Complications of Deep Brain Stimulation , 2002, Neurosurgery.

[99]  S. Imam,et al.  The Protective Role of l‐Carnitine against Neurotoxicity Evoked by Drug of Abuse, Methamphetamine, Could Be Related to Mitochondrial Dysfunction , 2002, Annals of the New York Academy of Sciences.

[100]  P. Mander,et al.  Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration , 2002, Neuroscience.

[101]  R. Mayeux,et al.  Smoking and Parkinson’s disease in twins , 2002, Neurology.

[102]  T. Montine,et al.  Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans , 2002, Neuroscience Letters.

[103]  B. Wolozin,et al.  Book Review: Iron and Parkinson’s Disease , 2002, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[104]  A. Schapira.  Neuroprotection and dopamine agonists , 2002, Neurology.

[105]  R. Pfeiffer.  Potential of Transdermal Drug Delivery in Parkinson’s Disease , 2002, Drugs & aging.

[106]  B. Crestani,et al.  Benefits and Risks of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease , 2002, Drug safety.

[107]  Alon Mogilner,et al.  Complications of Deep Brain Stimulation Surgery , 2002, Stereotactic and Functional Neurosurgery.

[108]  A. Quattrone,et al.  Plasma levels of vitamin E in Parkinson's disease. , 2001, Archives of gerontology and geriatrics.

[109]  Heredity in Parkinson's disease: new findings. , 2001, The Israel Medical Association journal : IMAJ.

[110]  R. Hubbard,et al.  Adverse effects of oral corticosteroids in relation to dose in patients with lung disease , 2001, Thorax.

[111]  J. Joseph,et al.  A possible emerging role of phytochemicals in improving age-related neurological dysfunctions: a multiplicity of effects. , 2001, Free radical biology & medicine.

[112]  Gene therapy for Parkinson's disease: determining the genes necessary for optimal dopamine replacement in rat models. , 2001, Human cell.

[113]  J. Shepherd.  Effects of estrogen on congnition mood, and degenerative brain diseases. , 2001, Journal of the American Pharmaceutical Association.

[114]  M. Roghani,et al.  Neuroprotective effect of vitamin E on the early model of Parkinson’s disease in rat: behavioral and histochemical evidence 1 1 Published on the World Wide Web 3 January 2001. , 2001, Brain Research.

[115]  B. Ferger,et al.  Inhibition of the cyclooxygenase isoenzymes COX‐1 and COX‐2 provide neuroprotection in the MPTP‐mouse model of Parkinson's disease , 2001, Synapse.

[116]  O. Lindvall,et al.  Cell Therapy and Transplantation in Parkinsons Disease , 2001, Clinical chemistry and laboratory medicine.

[117]  W. Koller,et al.  An algorithm (decision tree) for the management of Parkinson’s disease (2001): , 1998, Neurology.

[118]  Neurosurgery for Parkinson's disease. , 2001, Seminars in neurology.

[119]  D. Latchman,et al.  Viral Vectors for Gene Therapy in Parkinson's Disease , 2001, Reviews in the neurosciences.

[120]  T. Subramanian.  Cell Transplantation for the Treatment of Parkinson's Disease , 2001, Seminars in neurology.

[121]  H. Petrovitch,et al.  Current Evidence for Neuroprotective Effects of Nicotine and Caffeine Against Parkinson’s Disease , 2001, Drugs & aging.

[122]  I. Galve-Roperh,et al.  Control of the cell survival/death decision by cannabinoids , 2001, Journal of Molecular Medicine.

[123]  I. Mizuta,et al.  Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. , 2000, Biochemical and biophysical research communications.

[124]  M. Mattson,et al.  The lipid peroxidation product 4-hydroxy-2,3-nonenal inhibits constitutive and inducible activity of nuclear factor kappa B in neurons. , 2000, Brain research. Molecular brain research.

[125]  G. Wilkin,et al.  Inflammatory Regulators in Parkinson's Disease: iNOS, Lipocortin-1, and Cyclooxygenases-1 and -2 , 2000, Molecular and Cellular Neuroscience.

[126]  D. Schaid,et al.  Smoking, alcohol, and coffee consumption preceding Parkinson’s disease , 2000, Neurology.

[127]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[128]  C. Warren Olanow,et al.  Levodopa motor complications in Parkinson's disease , 2000, Trends in Neurosciences.

[129]  C. Sortwell,et al.  Time Course of Apoptotic Cell Death within Mesencephalic Cell Suspension Grafts: Implications for Improving Grafted Dopamine Neuron Survival , 2000, Experimental Neurology.

[130]  C. Humpel,et al.  Glial cell line-derived neurotrophic factor (GDNF) is a proliferation factor for rat C6 glioma cells: evidence from antisense experiments. , 2000, Antisense & nucleic acid drug development.

[131]  J. Rusted,et al.  Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer’s disease and Parkinson’s disease , 2000, Behavioural Brain Research.

[132]  T. Dawson,et al.  Oxidative Stress and Genetics in the Pathogenesis of Parkinson's Disease , 2000, Neurobiology of Disease.

[133]  K. Mohanakumar,et al.  Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 2000, Brain Research.

[134]  Chase Tn,et al.  Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. , 2000 .

[135]  S Fahn,et al.  The spectrum of levodopa-induced dyskinesias. , 2000, Annals of neurology.

[136]  P. Newhouse,et al.  Nicotinic systems in central nervous systems disease: degenerative disorders and beyond. , 2000, Pharmaceutica acta Helvetiae.

[137]  S. Harada,et al.  Cross-cultural traits for personality of patients with Parkinson's disease in Japan. , 2000, American journal of medical genetics.

[138]  K. Fuxe,et al.  Neurotrophic effects of central nicotinic receptor activation. , 2000, Journal of neural transmission. Supplementum.

[139]  Lieberman,et al.  The evolution and origin of motor complications in Parkinson's disease. , 2000, Neurology.

[140]  A. Hofman,et al.  Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. , 2000, Neurology.

[141]  G. Barja,et al.  Effect of MPTP on brain mitochondrial H2O2 and ATP production and on dopamine and DOPAC in the striatum. , 1999, Journal of physiology and biochemistry.

[142]  T. Montine,et al.  Endogenous catechol thioethers may be pro-oxidant or antioxidant. , 1999, Free radical biology & medicine.

[143]  J. McNeil,et al.  Predictors and Timing of Adverse Experiences During Transdermal Nicotine Therapy , 1999, Drug safety.

[144]  E. Castrén,et al.  Trophic effects of selegiline on cultured dopaminergic neurons , 1999, Brain Research.

[145]  S. Factor,et al.  Transient benefit of amantadine in Parkinson's disease: The facts about the myth , 1999, Movement disorders : official journal of the Movement Disorder Society.

[146]  E. Levin,et al.  Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer’s disease , 1999, Psychopharmacology.

[147]  K. Jellinger,et al.  The Role of Iron in Neurodegeneration , 1999, Drugs & aging.

[148]  T. Suda,et al.  Loss of regulation by presynaptic dopamine D2 receptors of exogenous l-DOPA-derived dopamine release in the dopaminergic denervated striatum , 1999, Brain Research.

[149]  C. C. Johnson,et al.  Smoking and Parkinson’s disease , 1999, Neurology.

[150]  Y. Agid,et al.  The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease. , 1999, Movement disorders : official journal of the Movement Disorder Society.

[151]  O. Rascol.  L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach. , 1999, Movement disorders : official journal of the Movement Disorder Society.

[152]  R. Elble.  Animal Models of Action Tremor , 2008, Movement disorders : official journal of the Movement Disorder Society.

[153]  F. Vaglini,et al.  Nicotine Prevents Experimental Parkinsonism in Rodents and Induces Striatal Increase of Neurotrophic Factors , 1998, Journal of neurochemistry.

[154]  P. Odin,et al.  Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up , 1998, Journal of neurology, neurosurgery, and psychiatry.

[155]  R. Reiter.  Oxidative damage in the central nervous system: protection by melatonin , 1998, Progress in Neurobiology.

[156]  F. Assal,et al.  Tolcapone and fulminant hepatitis , 1998, The Lancet.

[157]  J. Schneider,et al.  Effects of SIB‐1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys , 1998, Movement disorders : official journal of the Movement Disorder Society.

[158]  M. Brin,et al.  Levodopa neurotoxicity , 1998, Neurology.

[159]  S. Ruggieri,et al.  Initiating therapy for Parkinson's disease , 1998, Neurology.

[160]  F. Lezoualc’h,et al.  N‐acetyl‐serotonin (normelatonin) and melatonin protect neurons against oxidative challenges and suppress the activity of the transcription factor NF‐κB , 1998, Journal of Pineal Research.

[161]  L. Hansson,et al.  Long‐term intraduodenal infusion of a water based levodopa‐carbidopa dispersion in very advanced Parkinson's disease , 1998, Acta neurologica Scandinavica.

[162]  W. Tatton,et al.  Mitochondrial Membrane Potential and Nuclear Changes in Apoptosis Caused by Serum and Nerve Growth Factor Withdrawal: Time Course and Modification by (؊)-deprenyl , 2022 .

[163]  Smoking and Parkinson's disease , 1997, Neurology.

[164]  A. Rajput,et al.  Tolcapone improves motor function in parkinsonian patients with the"wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial , 1997, Neurology.

[165]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[166]  R. Reiter,et al.  Melatonin is protective against MPTP-induced striatal and hippocampal lesions. , 1996, Life sciences.

[167]  S. Mann,et al.  Ciba Foundation Symposium , 1997 .

[168]  M. Contin,et al.  Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease , 1996, Clinical pharmacokinetics.

[169]  N. Hattori,et al.  Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[170]  L. Forno,et al.  Neuropathology of Parkinson's Disease , 1996, Journal of neuropathology and experimental neurology.

[171]  Paul F. Smith,et al.  The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF). , 1996, Journal of ethnopharmacology.

[172]  J. Wagner,et al.  Amphiphilic α-tocopherol analogues as inhibitors of brain lipid peroxidation , 1996 .

[173]  H. Hasegawa,et al.  Ameliorative effects of tea catechins on active oxygen-related nerve cell injuries. , 1995, The Journal of pharmacology and experimental therapeutics.

[174]  M. Danhof,et al.  Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: A study of five different suppositories , 1995, Movement disorders : official journal of the Movement Disorder Society.

[175]  D. Morens,et al.  Cigarette smoking and protection from Parkinson's disease , 1995, Neurology.

[176]  J. Sage,et al.  Apomorphine for Motor Fluctuations and Freezing in Parkinson's Disease , 1995, The Annals of pharmacotherapy.

[177]  O. Rascol,et al.  Sublingual apomorphine: a new pharmacological approach in Parkinson's disease? , 1995, Journal of neural transmission. Supplementum.

[178]  E. Broussolle,et al.  Apomorphine in patients with Parkinson's disease. , 1995, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[179]  R. Ramsay,et al.  Characterization of the inhibitory mechanism of 1-methyl-4-phenylpyridinium and 4-phenylpyridine analogs in inner membrane preparations. , 1994, The Journal of biological chemistry.

[180]  C. Prasad,et al.  Chronic nicotine intake decelerates aging of nigrostriatal dopaminergic neurons. , 1994, Life sciences.

[181]  J. Langston,et al.  Double‐blind, placebo‐controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on‐off' fluctuations , 1993, Neurology.

[182]  B. Hyman,et al.  Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: A stereological estimate of neuronal loss , 1993, Neurobiology of Aging.

[183]  L. Golbe,et al.  Dopamine‐related personality traits in Parkinson's disease , 1993, Neurology.

[184]  P. Riederer,et al.  The possible role of iron in the etiopathology of parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.

[185]  J. C. Stoof,et al.  Amantadine as N-methyl-d-aspartic acid receptor antagonist: new possibilities for therapeutic applications? , 1992, Clinical Neurology and Neurosurgery.

[186]  S. Fahn,et al.  The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.

[187]  D. Calne.  The free radical hypothesis in idiopathic parkinsonism: Evidence against it , 1992, Annals of neurology.

[188]  T. van Laar,et al.  Rectal apomorphine: a new treatment modality in Parkinson's disease. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[189]  S. Gauthier,et al.  Sustained Release Antiparkinson Agents: Controlled Release Levodopa , 1992, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[190]  S. Fahn.  A pilot trial of high‐dose alpha‐tocopherol and ascorbate in early Parkinson's disease , 1992, Annals of neurology.

[191]  O. Rascol,et al.  Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms. , 1991, British journal of clinical pharmacology.

[192]  J. Rinne,et al.  Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease , 1991, Neurology.

[193]  N. Dadmehr,et al.  Is there a premorbid personality typical for Parkinson's disease? , 1991, Neurology.

[194]  P Riederer,et al.  Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains , 1991, Journal of neurochemistry.

[195]  A. Hughes,et al.  Rectal apomorphine in Parkinson's disease , 1991, The Lancet.

[196]  M. Ghilardi,et al.  Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates , 1991, Journal of neural transmission. Parkinson's disease and dementia section.

[197]  S. Fahn.  An open trial of high-dosage antioxidants in early Parkinson's disease. , 1991, The American journal of clinical nutrition.

[198]  Y. Christen,et al.  Prevention by a Ginkgo biloba Extract (GBE 761) of the Dopaminergic Neurotoxicity of MPTP , 1990, The Journal of pharmacy and pharmacology.

[199]  J. Hubble,et al.  Levodopa therapy in Parkinson's disease , 1990, Neurology.

[200]  J G Nutt,et al.  Levodopa‐induced dyskinesia , 1990, Neurology.

[201]  G. Bock,et al.  Ciba Foundation Symposium 152 - The Biology of Nicotine Dependence , 1990 .

[202]  G. Bock,et al.  The Biology of nicotine dependence , 1990 .

[203]  K. Lyons,et al.  Therapy of Parkinson's disease , 1990 .

[204]  G. Cohen,et al.  Deprenyl suppresses the oxidant stress associated with increased dopamine turnover , 1989, Annals of neurology.

[205]  C. Goetz,et al.  Hypersexuality with antiparkinsonian therapy. , 1989, Clinical neuropharmacology.

[206]  H. Fibiger,et al.  Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. , 1988, The Journal of pharmacology and experimental therapeutics.

[207]  R. Duvoisin,et al.  Long‐term duodenal infusion of levodopa for motor fluctuations in parkinsonism , 1988, Annals of neurology.

[208]  L. Herzberg.  Dr James Parkinson. , 1987, Clinical and experimental neurology.

[209]  Rajesh Pahwa,et al.  Stroke , 1987, Neurology.

[210]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[211]  B. Katzung.  Basic and Clinical Pharmacology , 1982 .

[212]  G. Stern,et al.  LITHIUM IN PARKINSON'S DISEASE , 1974 .

[213]  J. Parkinson.  AN ESSAY ON THE SHAKING PALSY , 1969 .